All
Chari Considers Choosing Proteasome Inhibitors in Relapsed Multiple Myeloma
August 29th 2019During a Targeted Oncology case-based peer perspectives presentation, Ajai Chari, MD, discussed with a group of physicians the treatment options available to patients with relapsed multiple myeloma. Chari explained the various treatment options and the supporting data based around a case scenario of a patient with multiple myeloma who relapses.
Phase II Data Suggest Predictive Value of Preexisting CD8+ T Cells in SCLC
August 28th 2019Findings from a phase II study in patients with small cell lung cancer suggested tumor immune phenotypes can be predictive of response to immune checkpoint blockade. Responses to the combination of durvalumab plus olaparib were observed in all patients where tumors had an inflamed phenotype.
Investigational FGFR4 Inhibitor Shows Early Signs of Activity in HCC and ICC
August 28th 2019In an interview with Targeted Oncology, Martin E. Gutierrez, MD, discussed the findings from the first-in-human phase I study investigating H3B-6527 in patients with HCC and ICC. He also highlighted the potential role for combination therapy with H3B-6527 and the next steps planned for subsequent phase II and III trials in HCC and ICC.
Enzalutamide With Gemcitabine and Cisplatin Safely Targets AR+ Metastatic Bladder Cancer
August 28th 2019In an interview with <em>Targeted Oncology</em>, Shilpa Gupta, MD, discussed the results of the phase I/Ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer and defining platinum ineligibility in patients with metastatic urothelial cancer.
PD-L1 Associated With Aggressive MTC, Suggests Potential for PD-1 Checkpoint Inhibitors
August 27th 2019PD-L1 positivity in patients with medullary thyroid cancer is associated with more aggressive clinicopathological features and predictive of structural and biochemical recurrences, according to the results of a retrospective Chinese study.
PFS Doubling Observed in Patients With EGFR+ NSCLC With Addition of Platinum to Gefitinib
August 26th 2019The addition of carboplatin and pemetrexed to therapy with gefitinib in patients with non–small cell lung cancer and an <em>EGFR</em>-sensitizing mutation had a statistically significant effect on progression-free survival and overall survival and represents a new therapy option for these patients.
Ruxolitinib and Buparlisib Combo Considered in Early Myelofibrosis Study
August 26th 2019A dose-finding phase Ib study successfully evaluated a combined regimen of oral ruxolitinib and buparlisib in adult patients with intermediate- or high-risk primary or secondary myelofibrosis for safety and efficacy.
Marshall Examines TKIs and Immunotherapy Agents for GI Cancers
August 24th 2019John L. Marshall, MD, spoke with a group of physicians during a Targeted Oncology live case-based peer perspectives discussion on the different classes of agents available to treat patients with gastrointestinal cancers.
Expert Discusses Challenges and Future Opportunities in Treating Myelofibrosis
August 23rd 2019In an interview with <em>Targeted Oncology</em>, McCloskey discussed current treatment options for patients with myelofibrosis as well as further options in development in clinical trials. McCloskey recommended that community oncologists partner with specialists to improve the prognosis for these patients until new agents are approved, and for referrals to clinical trials for further research for this patient population.
FCS and Cigna Create New Initiative Focused on Better Patient Experience
August 23rd 2019Florida Cancer Specialists & Research Institute has announced an oncology-focused initiative with Cigna as a part of the Cigna Collaborative Care. The Cigna Oncology Focus program's main goal is to provide quality care and contain costs for people with cancer. It also uses incentives to encourage healthcare professionals to improve affordability, as well as patients health and overall experience.
Early Data From DREAMM-2 Trial Promising for Belantamab Mafodotin in Relapsed Multiple Myeloma
August 23rd 2019Belantamab mafodotin, an investigational antibody–drug conjugate, demonstrated a clinically meaningful overall response rate among patients with relapsed multiple myeloma in early results from the DREAMM-2 trial, according to a press release from GlaxoSmithKline. This met the primary endpoint of the pivotal phase II trial.
Expert Highlights Data that Led to the Approval of Fedratinib in Myelofibrosis
August 23rd 2019In an interview with <em>Targeted Oncology</em>, Ruben Mesa, MD, discussed the results from the reanalysis of the JAKARTA-2 trial that led to the approval of fedratinib in patients with MF. He also highlighted the role of the FREEDOM study that is currently enrolling patients with MF for treatment with fedratinib.
Selinexor Induces Meaningful Survival in Heavily Pretreated Multiple Myeloma in STORM Trial
August 22nd 2019Selinexor plus dexamethasone induced objective responses and a significant overall survival among heavily pretreated patients with multiple myeloma, according to results from the phase IIb STORM trial published in <em>The New England Journal of Medicine.</em>
Precision Medicine Trials and Molecular Testing Guidelines Expand to Reach More Patients
August 21st 2019During the <em>20th Annual </em>International Lung Cancer Congress, <em>Targeted Oncology</em> spoke with another Lung-MAP investigator, Fred R. Hirsch, MD, PhD, about the status and importance of the trial and new recommendations for molecular testing and liquid biopsies working their way into practice in the lung cancer field.
OS Results Fall Flat With Durvalumab/Tremelimumab Combo in NEPTUNE Trial
August 21st 2019The combination of durvalumab and tremelimumab did not meet its primary overall survival endpoint compared with platinum-based chemotherapy in patients with previously untreated stage IV non–small cell lung cancer and a high tumor mutational burden, according to final OS results from the phase III NEPTUNE trial.
Expert Says Talazoparib Plus Enzalutamide May Change the Standard of Care for Prostate Cancer
August 20th 2019In an interview with <em>Targeted Oncology</em>, Agarwal, professor of medicine at the Huntsman Cancer Institute, University of Utah, gave an overview of the TALAPRO-2 trial and discussed its potential for changing the standard of care for patients with mCRPC.
Triplet Combination With Vorinostat Shows High Response Rate in Frontline MCL
August 20th 2019A combination of vorinostat, cladribine, and rituximab demonstrated high, durable rates of complete response in patients with previously untreated mantle cell lymphoma, according to the results of a phase I/II trial of the triplet regimen in patients with non-Hodgkin lymphoma.<br />
Manji Advises on Community Oncologists Targeting Molecular Markers in Patients with Colon Cancer
August 19th 2019In an interview with <em>Targeted Oncology</em> following his presentation at the <em>3rd Annual</em> Congress on Oncology & Pathology hosted by PER®, Gulam A. Manji, MD, discussed the emergence of new therapies for targeting mutations in patients with colon cancer.
Raghav Works Through a CRC Patient Case After First-and Second-Line Therapy Exhaustion
August 17th 2019At a recent Targeted Oncology live case-based peer perspectives event, Kanwal P. S. Raghav, MBBS, MD, presented a case scenario of a patient with colorectal cancer who has already gone through first- and second-line treatments. Raghav explained the treatment considerations he would make with similar patients in the clinic and the treatment options available to this patient with CRC in this setting.
FDA Approves Fedratinib for the Treatment of Primary/Secondary Myelofibrosis
August 16th 2019The FDA has approved the treatment of fedratinib for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
Ibrutinib Remains Well Tolerated in Elderly Patients With CLL at 5-Year Follow-Up
August 16th 2019In an interview with Targeted Oncology, Alessandra Tedeschi, MD, discussed the 5-year data she presented at the 2019 EHA Meeting for frontline ibrutinib as a treatment for patients with CLL. She also highlighted other research that may also benefit elderly patients with CLL, including the emerging combination of venetoclax and obinutuzumab.
FDA Approves Entrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors
August 16th 2019The FDA has approved entrectinib for the treatment of adult patients with <em>ROS1</em>-positive metastatic non–small cell lung cancer. An accelerated approval was also granted to entrectinib for the treatment of adult and adolescent patients with solid tumors harboring an <em>NTRK </em>gene fusion and who have no alternative, effective therapies available.